WallStreetZenWallStreetZen

NYSEMKT: TOVX
Theriva Biologics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their TOVX stock forecasts and price targets.

Forecast return on equity

Is TOVX forecast to generate an efficient return?

Company
N/A
Industry
66.38%
Market
180.26%

Forecast return on assets

Is TOVX forecast to generate an efficient return on assets?

Company
N/A
Industry
31.55%

TOVX earnings per share forecast

What is TOVX's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.55
Avg 2 year Forecast
-$1.60

TOVX revenue forecast

What is TOVX's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$26.2M

TOVX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TOVX$0.19N/AN/A
BOLT$4.44$7.00+57.66%Buy
ERNA$0.29N/AN/A
PHGE$5.23$26.00+397.13%Buy
RNAZ$9.68N/AN/A
View Top Biotech Stocks

Theriva Biologics Stock Forecast FAQ

What is TOVX's earnings growth forecast for 2026-2027?

(NYSEMKT: TOVX) Theriva Biologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.91%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.23%.

Theriva Biologics's earnings in 2026 is -$25,249,000.On average, 4 Wall Street analysts forecast TOVX's earnings for 2026 to be -$70,917,940, with the lowest TOVX earnings forecast at -$102,542,577, and the highest TOVX earnings forecast at -$36,140,476.

In 2027, TOVX is forecast to generate -$73,258,466 in earnings, with the lowest earnings forecast at -$95,796,355 and the highest earnings forecast at -$48,187,301.

If you're new to stock investing, here's how to buy Theriva Biologics stock.

What is TOVX's revenue growth forecast for 2026-2028?

(NYSEMKT: TOVX) Theriva Biologics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.48%.

Theriva Biologics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast TOVX's revenue for 2026 to be $0, with the lowest TOVX revenue forecast at $0, and the highest TOVX revenue forecast at $0. On average, 3 Wall Street analysts forecast TOVX's revenue for 2027 to be $0, with the lowest TOVX revenue forecast at $0, and the highest TOVX revenue forecast at $0.

In 2028, TOVX is forecast to generate $1,204,269,501 in revenue, with the lowest revenue forecast at $1,157,000,053 and the highest revenue forecast at $1,239,652,748.

What is TOVX's forecast return on assets (ROA) for 2026-2029?

(NYSEMKT: TOVX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 31.55%.

What is TOVX's Earnings Per Share (EPS) forecast for 2026-2027?

(NYSEMKT: TOVX) Theriva Biologics's current Earnings Per Share (EPS) is -$2.08. On average, analysts forecast that TOVX's EPS will be -$1.55 for 2026, with the lowest EPS forecast at -$2.23, and the highest EPS forecast at -$0.79. In 2027, TOVX's EPS is forecast to hit -$1.60 (min: -$2.09, max: -$1.05).

What is TOVX's forecast return on equity (ROE) for 2026-2029?

(NYSEMKT: TOVX) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.